A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation

Update Il y a 4 ans
Reference: EUCTR2009-009862-15

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Primary safety objective: To evaluate the dose-response relationship for QT effects of AZD1305 Primary efficacy objective: To demonstrate a dose-response relationship for AZD1305 given intravenously for conversion of AF to SR, and a statistically significant pair-wise difference for at least one of the dose levels of AZD1305 versus placebo


Inclusion criteria

  • Atrial fibrillation clinically indicated for cardioversion